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Abstract
INTRODUCTION—Varicella vaccines are highly effective at preventing disease, but varicella 
may occur among vaccinated persons (termed breakthrough varicella). Breakthrough varicella is 
generally mild, but severe cases have been reported. The objective of this review is to describe 
severe breakthrough varicella.
AREAS COVERED—We conducted a systematic review of articles published during 1974–
2016. A total of 34 articles were included in our review: 21 described breakthrough varicella with 
disseminated varicella-zoster virus (VZV) infection with other organ involvement in addition to 
skin (none among two-dose vaccinees); 9 described hospitalized breakthrough varicella without 
mention of other organ involvement in addition to skin (of which 2 reported 4 two-dose 
vaccinees); and 4 described both. A total of 52–60 unique breakthrough varicella cases with 
disseminated VZV infection with other organ involvement in addition to skin reported with the 
following complications, not mutually exclusive: pneumonia (n=8–9 cases), neurologic (n=18–24 
cases), hematologic (n=10–11 cases), ocular (n=5 cases), renal (n=2 cases), hepatic (n=3 cases), 
secondary infection with bacteremia or sepsis (n=8 cases), and other complication (n=4 cases). 
There were 6 cases of fatal breakthrough varicella.
EXPERT COMMENTARY—With >31 million doses distributed annually worldwide since 2007, 
severe breakthrough varicella can occur but they appear to be uncommon.
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Varicella (chickenpox) is a highly contagious disease caused by infection with varicella-
zoster virus (VZV). It presents as a generalized maculopapulovesicular rash with ~250–500 
lesions. Varicella is usually a self-limited disease1 but can cause significant morbidity and 
can lead to death, more commonly in immunocompromised patients, with skin and soft 
tissue infections, pneumonia, and encephalitis being the most frequent complications2, 3. A 
varicella vaccine containing live-attenuated VZV (named Oka strain) was developed in 
Japan in the early 1970s4. Several licensed varicella vaccines are available, all using live-
attenuated VZV and all based on the Oka strain except the vaccine developed in South 
Korea5. The vaccine is available as a single-antigen vaccine or in combination with measles, 
mumps, and rubella (MMRV). While the varicella vaccines are licensed worldwide, varicella 
vaccination is routinely recommended in a limited number of countries, either as a one or 
two-dose program6–8. Varicella vaccine is not recommended for most immunocompromised 
persons3. The United States was the first country to recommend a routine one-dose program 
in 1996, then updated its recommendations to a routine two-dose program in 20063.
Varicella vaccine is safe and effective at preventing varicella9–12. One dose is approximately 
81% effective against any clinical disease and >95% effective against combined moderate 
and severe varicella; the second dose provides additional protection against any 
varicella9, 13, 14. Varicella due to wild-type (WT)-VZV may occur in some persons 
vaccinated with varicella vaccine after exposure to WT-VZV and is termed breakthrough 
varicella (i.e., vaccine failure). Breakthrough varicella is generally milder in severity and 
duration than varicella in unvaccinated persons1; clinical symptoms usually consist of a rash 
with <50 lesions, predominately maculopapular although sometimes also with vesicular 
lesions15. However, there have been cases of breakthrough varicella that resulted in 
extensive rash, complications, and even death1, 16. A systematic review of severe 
breakthrough varicella has not been performed to date. Understanding the range of severe 
complications of varicella among vaccinated persons is an important component of 
evaluating the varicella vaccination program. The objective of this literature review is to 
summarize and describe severe breakthrough varicella.
2. Methods
2.1 Literature search
We searched the PubMed Database for articles published from November 30, 1974, when 
information on varicella vaccine was first published, through August 1, 2016 using the 
following search terms: “(varicella or VZV or varicella-zoster virus or chickenpox) and 
(“breakthrough” or “vaccine failure” or “adverse event” or “vaccine effectiveness” or 
“vaccine safety” or “vaccinated” or “immunized”)”.
We reviewed each title and abstract to determine if the article might include data on 
breakthrough varicella cases. For articles that passed this initial screen, we reviewed the full 
text if the article was available in English; if the full text was not available in English, we 
used the information from the abstract. We also reviewed any additional references that 
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described breakthrough varicella that were identified from the reference section of the 
articles reviewed and were not retrieved by the PubMed search.
2.2 Definitions
Breakthrough varicella is defined as varicella in a person who received at least one dose of 
varicella vaccine (single-antigen or MMRV vaccines) ≥42 days before occurrence of 
symptoms, without other apparent cause17. Forty-two days, which equals two incubation 
periods for varicella1, is used to differentiate breakthrough cases from potential vaccine-
strain varicella-like rashes. Post-licensure experience showed that vaccine-strain rashes 
occurred typically 21 days post-vaccination with a range of 5–42 days post-vaccination18.
For the purpose of our review, we defined severe breakthrough varicella as breakthrough 
varicella that resulted in 1) disseminated VZV infection with other organ involvement in 
addition to skin: pneumonia, complications related to nervous, hematologic, ocular, renal, 
and hepatic systems, sepsis and secondary infection resulting in bacteremia, and other 
complications, 2) any hospitalizations in addition to cases that met the first criterion, or 3) 
death. For articles that described severe breakthrough varicella, we abstracted, when 
available, data on number of breakthrough varicella cases reported, vaccine type, number of 
vaccine doses, age of vaccination, immune status or medication of case-patients, interval 
between vaccination and breakthrough varicella onset, complications, laboratory test results, 
and if hospitalized.
We excluded cases of 1) varicella due to vaccine-strain VZV, 2) re-activation (due to either 
vaccine-strain or WT-VZV) that were diagnosed as herpes zoster (shingles) or had a rash 
suggestive of herpes zoster, and 3) varicella-like illness in persons who had received herpes 
zoster vaccine, which is recommended for persons aged ≥60 years in the United States19.
Two co-authors reviewed each article and classified severe breakthrough varicella according 
to our case definition (including classification by organ system category). When questions 
arose about the case classification, the articles were reviewed by and discussed with the third 
co-author (physician). A breakthrough case may have had multiple complications and be 
described in more than one organ system category. We present the number of articles that 
described severe breakthrough varicella and the number of unique cases. Due to the use of 
the same surveillance systems in some publications it is likely that some of the cases were 
presented more than once; thus, it was difficult to determine the total number of unique 
cases. Therefore, we included a range based on our determination of the information 
presented in the articles.
3. Results
We identified and screened 915 articles published between 1974 and 2016 (Figure 1). Of the 
215 articles that described potential breakthrough varicella cases (publication years: 1977 to 
2016), 34 met inclusion criteria for our review (publication years: 1980 to 2016): 21 articles 
described breakthrough varicella cases with disseminated VZV infection with other organ 
involvement in addition to skin; 9 articles described hospitalized breakthrough varicella 
cases without mention of other organ involvement in addition to skin; 4 articles described 
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both [Figure 1, Table 1], for a total of 52–60 unique breakthrough varicella cases with 
disseminated VZV infection with other organ involvement in addition to skin and 266 
hospitalized breakthrough cases without mention of other organ involvement in addition to 
skin. Varicella cases with disseminated VZV infection are described below; range accounts 
for cases we identified that potentially were reported in multiple publications (Table 2). 
Most (20) of the articles described severe breakthrough varicella after receipt of Merck 
varicella vaccine products licensed in the United States [Table 1]; this is likely due to the 
United States being the country with the longest duration of a routine varicella vaccination 
program, and with the majority of the post-licensure varicella vaccine safety articles20.
No articles indicated severe breakthrough varicella cases with disseminated VZV infection 
with other organ involvement in addition to skin in a person who received 2 doses of 
varicella vaccine. There were 2 articles that indicated hospitalized breakthrough varicella 
cases without mention of other organ involvement in addition to skin in 4 patients who 
received 2 doses of varicella vaccine21, 22, although in 1 paper21 it was unclear whether 2 of 
these patients were breakthrough cases or the vaccine was received <42 days before rash 
onset.
3.1 Pneumonia
We identified 5 articles that described breakthrough varicella cases with pneumonia. Most 
pneumonia cases were identified in articles describing results of post-licensure vaccine 
surveillance. Using data from an active surveillance project, Chaves et al15, reported 1 case 
of pneumonia among 1,661 breakthrough cases in children aged 1–14 years during 1997–
2005 in the United States. Dinleyici et al23 reported 4 cases of pneumonia among a total of 
36 hospitalized breakthrough cases in children from 29 health care centers in Turkey; these 
cases were identified as part of a national prospective study on pediatric varicella 
hospitalizations during 2008–2013.
Galea24 et al reported 2 cases of pneumonia in immunocompetent persons out of 5,054 cases 
of breakthrough varicella based on Merck’s post-marketing worldwide surveillance data 
1995–2005. Quian et al25 reported 1 pneumonia case in a hospitalized 5 year-old with 
varicella who had been vaccinated at age 3 years among 462 varicella-related 
hospitalizations, of which 6 were breakthrough varicella, during 1997–2005 in Uruguay. 
Pileggi et al26 reported a breakthrough varicella case with pneumonia and probable 
macrophage activation syndrome in a patient with juvenile rheumatic disease who was on 
methotrexate (and possibly other immunosuppressive drugs) at the time of vaccination. The 
patient was a nonresponder to varicella vaccine based on serology testing using commercial 
assays. The patient developed severe breakthrough varicella after a known exposure to WT-
VZV 2–3 years after vaccination; the patient was receiving antitumor necrosis factor therapy 
at the time of exposure.
3.2 Neurologic complications
We identified 11 articles that described breakthrough cases with neurologic complications; 
diagnoses included meningitis, encephalitis, acute cerebellar ataxia, transverse myelitis, and 
cerebellitis. Seven articles described meningitis cases. Dinleyici et al23 reported 9 
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breakthrough cases with meningitis/encephalitis in their study of pediatric varicella 
hospitalizations; no additional information was provided on these cases. In the review of 
national safety data of varicella vaccine in the United States 1995–2005, Chaves et al10, 
described 4 cases of meningitis associated with breakthrough varicella in children aged ≤12 
years, 2 of whom had a CSF specimen positive for VZV by PCR, strain type not indicated. 
One of the laboratory confirmed cases was also described in a case report by Schwab et al27. 
This was a healthy 5 year-old who developed meningitis without ataxia who presented with 
fever, headache and rash. The patient had received varicella vaccine at age 3 years and 
developed varicella 18 months after vaccination. Upon treatment with acyclovir the patient 
made an uneventful recovery but at the 6 week follow-up visit, demonstrated mild to 
moderate sensorineural hearing loss on the right side. Two years later, the patient’s hearing 
was normal. In their review of the safety of varicella vaccine using Merck’s post-marketing 
worldwide surveillance database for 1995–2005, Galea et al24 reported 1 aseptic meningitis 
case in an immunocompetent patient with breakthrough varicella; no other details provided. 
Sharrar et al18 reported 1 hospitalized breakthrough varicella case with meningitis. The 
database used by these two publications was the same, with the Galea et al24 article covering 
the period analyzed by Sharrar et al18; it is likely that these were the same cases. Reynolds et 
al28 reported breakthrough varicella with meningitis in a 5 year-old with asthma. The child 
was admitted to the intensive care unit for 1 day for meningitis, and discharged with a 
diagnosis of altered mental status/post-varicella syndrome; by 6 weeks the child’s mental 
status had returned to normal.
Naruse et al29 described a 45-month old boy in Japan hospitalized with breakthrough 
varicella and meningitis vaccinated 21 months earlier with the Biken vaccine. After exposure 
to a child with varicella, the patient developed a rash (97 lesions), and headache and frequent 
vomiting 2 days after rash onset. The patient responded to intravenous (IV) acyclovir with 
resolution of symptoms within 2 days of treatment initiation and had no recurrent symptoms. 
His cerebrospinal fluid (CSF) specimen was positive for VZV DNA by PCR; type 
information not provided.
Breakthrough cases with encephalitis were described in 3 articles. One is the publication by 
Dinleyici et al23 that reported 9 breakthrough cases with encephalitis/meningitis. Chaves et 
al15, reported 1 case of breakthrough varicella with encephalitis in a healthy 4 year-old in the 
study from the varicella active surveillance project. Ibraheem et al30 described a 4 year-old 
girl without a known immunocompromising condition, who died from VZV encephalitis. 
Her past medical history included a nasal septum perforation with recurrent sinusitis, and 
hypocalcemia-related seizures at 1 year of age. She was vaccinated with 1 dose at age 13 
months. The patient was admitted with sudden severe headache and right eye pain. She did 
not have a rash. The patient’s condition worsened during hospitalization and she died on day 
6 of hospitalization. PCR of post-mortem brain specimens were positive for WT-VZV DNA 
and VZV encephalitis was the likely cause of death30. Of note, the authors mentioned that in 
the absence of the rash they were unable to determine whether the patient’s encephalitis was 
because of breakthrough infection or herpes zoster.
Acute cerebellar ataxia was described in 2 articles. Sharrar et al18 and Galea et al24 reported 
2 hospitalized breakthrough varicella cases with ataxia and 2 immunocompetent case-
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patients with breakthrough varicella and ataxia, respectively. As above there is the 
possibility of overlap due to the use of the same database.
Two case-reports described breakthrough varicella with transverse myelitis diagnosed after 
the rash had resolved. LaRovere et al31 described a case in an immunocompetent 14 year-old 
boy, vaccinated at 6 years of age. He developed fever and a generalized papulovesicular rash 
that lasted 6 days. Six days after his rash resolved, the patient reported a sharp “mid-scapular 
pain that radiated to his chest”, and 2 days later, he developed bilateral leg paresthesias and 
weakness, unsteady gait, and urinary retention. VZV antibody was detected in CSF. After 15 
days of hospitalization, his neurologic examination was normal although he still had 
weakness in his extremities. Two months after presentation, he was asymptomatic and his 
neurologic exam was normal. Aslan et al32 described a case in a 10 year-old girl without 
identified immunosuppressive conditions or medications who was vaccinated at age 12 
months. She was hospitalized with lower extremity paralysis and urinary retention. She had 
developed a mild rash (20–25 lesions) without fever, 16 days before hospitalization that 
lasted approximately 2 days. Fourteen days after the rash resolved, she developed bilateral 
leg paralysis, weakness, and unsteady gait. Her blood was positive for VZV IgG and IgM 
antibodies and the serum/CSF ratio of VZV antibody was reduced compared with ratios for 
total IgG and albumin, consistent with intrathecal synthesis of VZV antibody33. One month 
after hospitalization, the patient was asymptomatic and MRI showed normal findings of 
spinal cord.
Dinleyici et al23 reported 1 breakthrough case with cerebellitis based on hospital 
surveillance data from Turkey, without additional details.
3.3 Hematologic complications
There were 9 articles describing hematologic complications in 11 patients; diagnoses 
included neutropenia, thrombocytopenia, pancytopenia, possible macrophage activation 
syndrome, hemorrhagia, and disseminated intravascular coagulation (DIC). Dinleyici et al23 
reported 4 breakthrough cases with hematologic complications: 2 with neutropenia (of 
which one was febrile neutropenia) and 2 with thrombocytopenia. The previously mentioned 
case described by Pillegi et al26 with pneumonia, also developed probable macrophage 
activation. Kakish et al34 described a breakthrough case in a previously healthy 4 year-old 
child who developed varicella 12 weeks after varicella vaccination. He had a 2-day history 
of fever and maculopapulovesicular rash, when he presented with ecchymotic patches on the 
elbows and multiple purpuric skin lesions around the eyes with bilateral subconjunctival 
hemorrhages. His 3 year-old sibling had recovered from varicella 10 days previously. He 
was diagnosed with pancytopenia which was not responsive to multiple treatments (IV 
immune globulin, platelet transfusion, pulse dose corticosteroids, granulocyte colony 
stimulating factor). Bone marrow aspirate showed scarcity of all cell lines. Bone marrow 
transplant was recommended. Follow up information was not reported.
Hemorrhagia was described in 2 articles. Chaves et al15 reported 1 breakthrough varicella 
case with hemorrhagia in a study using active surveillance data; no other details were 
provided. Reynolds et al28 reported 1 breakthrough varicella case in a previously healthy 2 
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year-old who developed bleeding diathesis. These 2 papers used the same data source with 
overlapping years of data analyzed; it is possible that both describe the same case.
DIC was reported in 2 cases18, 35, 36. These cases are described under the complication we 
considered initiated the chain of events that led to DIC (hepatic complications and sepsis, 
respectively). Lastly, Leung et al16 described a fatal breakthrough case in a 7 year-old with 
malignant ependymoma and on dexamethasone (2 mg/day) who developed 
thrombocytopenia during the course of her illness; this case was also reported by Galea et 
al24. Limited clinical information was available on this case.
3.4 Ocular complications
There were 5 articles that described 5 breakthrough varicella patients with ocular 
complications, which included keratitis, conjunctivitis, subconjunctival hemorrhage, 
retinitis, blurred vision, and hemorrhagic retinitis. Galea et al24 reported 1 patient with 
breakthrough varicella and keratitis. Kurugol et al37 reported conjunctivitis in a 10 year-old 
healthy child from Turkey who developed breakthrough 9 years after receipt of 1-dose of 
varicella vaccine. The child was hospitalized for disseminated rash and fever and received 
oral and topical acyclovir for conjunctivitis; the patient fully recovered. The patient 
described above by Kakish et al34 with hematologic complications, also developed ocular 
complications (bilateral subconjunctival hemorrhages).
Ross et al38 described 1 breakthrough case in a 7 year-old child with T-cell acute 
lymphoblastic leukemia (ALL) in remission who developed varicella retinitis, blurred vision, 
and hemorrhagic retinitis. He was vaccinated with 1 dose at age 4, 27 months before he was 
diagnosed with ALL at age 6 years. He was VZV IgG positive at the time of his ALL 
diagnosis. He presented to the oncology clinic with high fever (104° F) and generalized 
vesicular rash and was clinically diagnosed with varicella. His last course of chemotherapy 
was 3 weeks before rash onset. He was exposed to a child with varicella in his school. After 
IV and oral acyclovir the rash resolved and the patient was discharged with all skin lesions 
crusted. Two weeks following varicella, he presented with blurred vision in the right eye, 
without new skin lesions. He developed a right afferent pupillary defect and superior 
temporal defect, and subsequently hemorrhagic retinitis in the inferotemporal quadrant. He 
was re-admitted, and received prolonged therapy with acyclovir and prednisolone 
ophthalmic drops that prevented progression of the retinitis. A residual scar remained in the 
area of previous retinitis.
Additionally, Dinleyici et al23 identified 1 hospitalized breakthrough varicella case with 
severe eye involvement; details of the ocular complications were not included.
3.5 Renal complications
There were 2 articles that described renal complications in 2 patients. Pillai et al39 
described a breakthrough case in a 24 year-old male with no history of renal disease or 
varicella who was vaccinated almost 2 years prior. He presented to the hospital with rash, 
gross hematuria, shaking chills, fever, and mild hypertension (130/94). Urinalysis revealed 
4+ protein, 4+ blood, many red blood cells (RBC), and granular casts. Blood pressure and 
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urinary abnormalities resolved in approximately 3 weeks; urinalysis 7 months later revealed 
3–5 RBCs. WT-VZV was cultured from skin lesion specimens. Goulleret et al11 reported 1 
case with renal complications out of 261 cases of breakthrough varicella based on Merck’s 
post-licensure surveillance data from Europe during 2003–2008. The case occurred in a 3 
year-old who was vaccinated at age 12 months, and 2 years later developed breakthrough 
varicella with nephrotic syndrome that required hospitalization. The child recovered 
completely. No specimens were collected for VZV laboratory testing.
3.6 Hepatic complications
There were 4 articles that described 3 cases of breakthrough varicella with hepatic 
complications including hepatomegaly, hepatitis, and hepatic necrosis. Nunoue et al40 
described 1 case with hepatomegaly. This was a child with acute leukemia treated with 
immunosuppressive therapy at the time of vaccination and after vaccination. She was 
vaccinated at age 3 years and developed varicella 11 months after vaccination. Her 
symptoms included fever, generalized rash (>100 lesions) that lasted 10 days, hepatomegaly, 
and elevated amino transferase levels. VZV culture was negative.
Kelley et al41 described 1 case with hepatitis that resulted in multi-organ failure and death; 
this death was also included in the summary of breakthrough varicella deaths in the paper by 
Leung et al16. This was a breakthrough case in a 15 year-old boy with T-cell precursor ALL 
who was undergoing reinduction chemotherapy and on Decadron (20 mg/day). He had 
received 1-dose of varicella vaccine at age 2 years (based on our earlier article16; Kelley et 
al41 reported he was vaccinated at age 5), and was up-to-date on other vaccinations. He 
presented with fever and a sharp stabbing back pain and 3 days later developed a rash 
described as nonvesiculated acne-like believed to be related to medication; on day 7 the rash 
started to vesiculate and PCR identified WT-VZV DNA in the vesicular fluid. On day 9 of 
illness, the patient developed hepatitis, and subsequently multi-organ failure and died. Wise 
et al36 and Sharrar et al18 each describe the same fatal breakthrough varicella case in a 9 
year-old girl with chronic severe asthma, on high-dose inhaled corticosteroids (60 mg/day, 
steroid not specified). This patient had received the 1st dose of varicella vaccine shortly 
before her 8th birthday. No rash had been recognized before death, but at autopsy, 2 of 
several scattered papules showed “intraepidermal vesicles with viral inclusions and 
multinucleated cells”. Autopsy disclosed fulminant hepatitis, esophagitis and epiglottitis, 
DIC and positive VZV cultures from pharynx, lung, blood, and urine; PCR identified WT-
VZV. Her liver was diffusely necrotic, and few surviving hepatocytes showed viral 
cytopathic changes.
3.7 Sepsis and Secondary Infection resulting in bacteremia
There were 7 articles that described sepsis (bacterial or viral) as a complication in 8 
breakthrough varicella cases. The specific organism that caused sepsis was reported in 3 
cases (Staph aureus or Group A streptococcus)18, 35, 36, 42. The first case was a fatal case of 
breakthrough varicella described by Sharrar et al18 and Wise et al36, mentioned above with 
hepatic complications that also developed Staph aureus sepsis. The second case, described 
by Kwak et al35, was in a previously healthy 38 month-old girl with necrotizing fasciitis on 
the left abdominal wall and streptococcal toxic shock syndrome; she was vaccinated at 12 
Leung et al. Page 8













months. Three days after onset of rash, she was seen in the emergency department for 
increased pain and swelling in the left flank. She had several ruptured blisters, macular rash, 
and painful purplish swelling surrounding some of the skin lesions on her left flank. 
Computerized tomography scan showed extensive soft tissue swelling of the left anterior 
abdominal wall, both flanks, and inguinal area and magnetic resonance imaging identified 
necrotizing fasciitis on the same sites. Group A Streptococcus was isolated by tissue culture. 
Laboratory investigation revealed disseminated intravascular coagulation. The patient 
recovered and was discharged after 5 weeks of hospitalization. The third case, described by 
Laskey et al42, was in a previously healthy 3 year-old boy who developed varicella 6 months 
after vaccination with no apparent skin infection, but the patient developed group A β-
hemolytic streptococcus (GABHS) bacteremia, resulting in endocarditis. Ten days after rash 
onset, the patient was admitted with a 3-day history of nausea, vomiting, fever along with 
increased irritability, decreased urine output and right foot pain with difficulty walking. 
Examination revealed crusted skin lesions without erythema, an I/VI systolic ejection 
murmur and worsening joint pain. On hospital day 2 blood cultures were positive for 
GABHS. The hospital course was complicated by bilateral pulmonary infiltrates, 
hypoalbuminemia, elevated liver function tests. On hospital day 8, the patient developed a 
diastolic murmur consistent with aortic regurgitation and subungal hemorrhages were noted. 
Echocardiography revealed thickening of the aortic valve with moderate aortic insufficiency. 
The patient was started on a 6-week treatment with IV penicillin G. However, after 2 weeks, 
the diastolic murmur was harsher and echocardiography revealed a large vegetation on the 
posterior leaflet of the aortic valve with severe aortic insufficiency and a dilated left 
ventricle. He was treated for congestive heart failure. A month after the initial 
echocardiography, the patient continued to have worsening aortic regurgitation and mitral 
regurgitation. The patient received an additional 4 weeks of antibiotic followed by aortic 
valve replacement. He had an unremarkable postoperative course and was doing well on 
follow-up examination.
There were 5 additional cases of sepsis reported, without information on the specific 
organism leading to sepsis, 3 alleged to be cases of bacterial sepsis. Dinleyici et al23 
identified 1 breakthrough varicella case in a child with leukemia who developed a secondary 
bacterial infection and sepsis, who ultimately died. Galea et al24 reported 2 breakthrough 
cases in immunocompetent persons who developed sepsis from secondary infection. The 7 
year-old patient with malignant ependymoma, described earlier with thrombocytopenia and 
reported by Galea et al24 and Leung et al16, also developed sepsis. This case had no evidence 
of bacterial infection (unpublished surveillance data). Sharrar et al18 reported an additional 
hospitalized breakthrough varicella case with dehydration and possible sepsis.
3.8 Other complications
Other complications included hypotension and transient hearing loss, which were described 
in the 2 cases mentioned above, reported by Kwak et al35 (described under sepsis) and 
Schwab et al27 (described under neurologic complications), respectively. Galea et al24 
reported 1 patient with breakthrough varicella who developed myocarditis; no other details 
were provided on this case. Kriner et al43 described 1 fatal breakthrough case in a patient 
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with ALL who developed multi-organ failure; she was on maintenance therapy (Vincristine/
dexamethasone).
3.9 Other Hospitalizations
Thirteen articles described a hospitalized breakthrough varicella case without mention of 
other organ involvement in addition to skin for a total estimated number of 266 
cases18, 21–23, 25, 28, 44–50. Eleven of these articles described data from various surveillance 
systems in different countries 18, 21–23, 25, 28, 44, 45, 47, 49, 50. Among 8 with information on 
total number of hospitalized varicella cases, in 7 the proportion of breakthrough 
hospitalizations among all varicella hospitalizations was 0–4%; in 1 the proportion was 
12%45. From 7 papers with information on the interval between varicella vaccination and 
hospitalization, the median interval was 0.8–4.7 years (range, 0.1–14 
years)18, 22, 23, 25, 28, 45, 50. Where information was provided, majority of these hospitalized 
cases occurred in immunocompromised children or adolescents and reasons for 
hospitalization included cellulitis, secondary bacterial infection limited to the skin, 
dehydration, or for precautionary reasons due to their immune status. Additionally, Yamada 
et al46 described 1 breakthrough varicella case in a 12 year-old cancer patient who was 
vaccinated at age 1. The patient was hospitalized for a prolonged rash for at least 14 days, 
with a maximum of 12 lesions at the peak of illness. Haddad et al48, described a varicella 
outbreak in a school, which involved one student with severe rash with >500 lesions who 
was hospitalized for 3 days and treated with IV antibiotics for Group A streptococcal 
secondary skin infection. Hospitalized breakthrough varicella with febrile seizure was 
reported by Dinleyici et al23 in Turkey (2 cases), Streng et al49 in Germany (2 cases) and 
Quian et al25 in Uruguay (1 case in a 2 year-old vaccinated 4 months previously).
3.10 Death
There have been 6 cases of fatal breakthrough varicella reported in 8 articles, all described 
above16, 18, 23, 24, 30, 36, 41, 43. Five of these deaths were reported from the United States and 
summarized in the article by Leung et al16, the 6th death was reported from Turkey by 
Dinleyici et al23. The deaths occurred in 1-dose vaccinees (interval between vaccination and 
death was 1–13 years; information available for 5 cases), in children aged <18 years (ages 4, 
4, 7, 9, 15 and <18 years) and 5 of the 6 occurred in immunocompromised persons due to 
either medical conditions or medications; the year of death was 1997, 2004, 2011, 2012, 
2013, and 2008–2013 for the death reported from Turkey (specific year of death not 
indicated in the publication). Reported complications included: hepatitis, hemorrhagia, and 
sepsis18, 36; sepsis and thrombocytopenia16, 24; hepatitis and multi-organ failure41; sepsis23; 
encephalitis30; and multi-organ failure43.
4. Expert Commentary and five-year view
Varicella vaccines have led to substantial declines in varicella disease3, 9, 10, 12, 51. The 
World Health Organization estimated an annual average of 31 million varicella vaccine 
doses distributed worldwide between 2007 and 201152; in the US >145 million doses of 
varicella vaccine have been distributed since program implementation through 2013. No 
vaccine is 100% safe or effective and adverse events following vaccination, and cases of 
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vaccine failure, including breakthrough varicella, have been reported. A review of the 
epidemiological and mechanistic (clinical and biological) evidence of selected adverse 
events after varicella vaccination associated with Oka VZV (i.e., vaccine-strain) was 
performed by the Institute of Medicine (IOM) in 201120. We focused our review on the 
occurrence of varicella due to wild-type VZV in previously vaccinated persons (i.e., vaccine 
failure), which was not reviewed by the IOM report.
This is the first systematic review to describe clinical characteristics and complications of 
severe varicella presentations among vaccinated children and summarize the information 
reported in the literature. Considering primarily the number of skin lesions, previous studies 
of varicella among vaccinated children described cases of breakthrough as mostly mild but 
indicate that ~25% of cases had clinical presentation more similar to unvaccinated 
children15. Most of these studies were not large enough to detect uncommon, serious 
complications of breakthrough varicella. Chaves et al53, reported that vaccinated children 
with ≥50 lesions were twice as likely to have complications, such as pneumonia, ataxia and 
skin superinfections, than vaccinated children with <50 lesions. Our review documented that 
severe complications with disseminated VZV infection with other organ involvement in 
addition to skin among breakthrough cases do occur but they appear uncommon. We found a 
similar pattern of complications in breakthrough varicella as compared to varicella in 
unvaccinated children with pneumonia, neurologic complications, and bacterial 
superinfection being most common2. Based on the number of published case-reports and 
cases identified by the post-marketing surveillance, severe complications of breakthrough 
varicella are likely less common than severe complications among unvaccinated patients. 
Ecologically, this statement is supported by evidence from studies that documented 
substantial declines in severe outcomes of varicella (i.e., hospitalizations and deaths) in 
countries with a varicella vaccination program16, 22, 49, 51, 54, 55. Even in the presence of a 
decline, when information on vaccination status was known, studies documented that the 
majority of hospitalizations which continue to occur are among unvaccinated patients.
Besides describing the types of complications and likely rarity of severe breakthrough 
varicella, our review allows for several other conclusions. First, although more frequent 
among immunocompromised children, severe breakthrough varicella-related outcomes can 
occur among healthy children too. Second, the data do not suggest that severe breakthrough 
varicella are more likely to occur with increased time since vaccination as most published 
cases occurred in children, rather than in young adults. Although we were not able to 
formally evaluate this question because of the lack of information on all cases, we found that 
majority of severe breakthrough cases that resulted in disseminated VZV infection with 
other organ involvement in addition to skin occurred within 5 years of varicella vaccination 
with 4 cases that occurred 8–13 years post-vaccination16, 31, 32, 37, 41; hospitalizations of 
breakthrough varicella without mention of other organ involvement in addition to skin 
occurred at a median of 0.8–4.7 years post-vaccination18, 22, 23, 25, 28, 45, 50. The question of 
whether severe breakthrough varicella is related to time since vaccination will be important 
to continue monitoring. Third, we did not identify any severe complications with 
disseminated VZV infection with other organ involvement in addition to skin among 2 dose 
vaccine recipients; there were 4 hospitalized breakthrough cases with skin infection who 
received 2 doses of varicella vaccine. Nonetheless, physicians should consider in the 
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differential diagnosis possible varicella-related complications when biologically plausible, 
even when varicella vaccine was received. Additionally, given the atypical presentations of 
breakthrough varicella, a diagnosis of varicella in vaccinated persons may not be readily 
made or a mild rash with few lesions may be missed altogether. Continued surveillance for 
varicella disease among vaccinated persons is important to evaluate the varicella vaccination 
program, detect any changes in the epidemiology of varicella in the context of a routine one- 
or two-dose varicella vaccination program, and understand the differences in disease 
presentation between persons who had received 1 or 2 doses of varicella vaccine.
Our review has several limitations. We were unable to calculate rates of complications for 
severe breakthrough varicella. It was challenging to determine the number of cases in each 
symptom category group since a case may have been reported in multiple articles. We 
indicated the potential overlap in reporting of the same breakthrough cases among different 
articles when information in the articles allowed us to make that determination. There was 
limited information on clinical course, medical history, and vaccination history for some of 
the cases with information often presented as aggregate data instead of case-level data. We 
may have missed severe breakthrough cases because of under-reporting; however, we believe 
that these cases would be more likely to be reported. Our literature review does not include 
data on all hospitalized breakthrough cases and therefore the number of hospitalizations we 
report should be interpreted with this caveat. The 12 articles included in our review 
described postlicensure surveillance from 9 countries and may have only included data on 
select populations or surveillance sites. Additionally, data from national datasets in the 
United States are not included because information on vaccination status is not available in 
these datasets. Nonetheless, in the articles included in our review, the proportion of 
breakthrough varicella cases among all varicella-related hospitalizations is small, ranging 
from 0 to 4%.
The majority of cases were clinically diagnosed. Confirmation as WT-VZV infection was 
limited (5 cases, with additional 3 cases with VZV DNA detected but not typed). Even for 
cases with laboratory-confirmed WT-VZV infection, we are unable to definitively link the 
complications to WT-VZV infection. Some of the complications could have also been 
caused by vaccine-strain VZV during primary infection or re-activation since the vaccine-
strain is a live virus. However, we minimized these possibilities by 1) excluding varicella-
like cases that occurred <42 days post-vaccination, which are more likely to represent 
vaccine-strain varicella cases, and 2) excluding cases diagnosed as herpes zoster or with 
localized rash suggestive of herpes zoster. Lastly, we excluded cases from one article that 
analyzed data from postlicensure surveillance systems in which severe outcomes were 
reported at varying intervals (6–128 days) after vaccination among persons who received 
varicella vaccine and that occurred in the absence of rash, a diagnosis of breakthrough 
varicella, or laboratory confirmation of VZV infection36; it is unlikely that these cases were 
associated with breakthrough varicella.
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• Severe varicella in vaccinated persons (breakthrough varicella) involving 
disseminated VZV infection with other organ involvement in addition to skin, 
other hospitalizations, or death can occur but they appear to be uncommon. 
Providers should consider varicella as part of the differential diagnosis of 
severe clinical presentations when biologically plausible, even if a person had 
received varicella vaccine; rapid antiviral treatment is important in these 
situations56.
• With >31 million varicella vaccine doses distributed annually worldwide 
since 2007, 34 published articles described severe breakthrough varicella; of 
them 25 described ~60 cases with disseminated VZV infection with other 
organ involvement in addition to skin. Complications of varicella are likely 
less common in persons who were vaccinated than those who were not 
vaccinated.
• Complications involving disseminated VZV infection with other organ 
involvement in addition to skin in persons with breakthrough varicella are 
similar to those seen in varicella among unvaccinated persons. These 
complications were reported among one-dose vaccine recipients only; none 
were reported among two-dose vaccine recipients.
• Of hospitalized breakthrough varicella cases without mention of other organ 
involvement in addition to skin, a few (4) were reported in two-dose vaccine 
recipients, but the majority were reported among one-dose vaccine recipients.
• Severe breakthrough varicella can occur among healthy persons, but appear to 
be more common among immunocompromised persons, who are usually not 
recommended to receive varicella vaccination.
• Varicella vaccines are safe and effective, and had a significant impact on 
reducing varicella morbidity and mortality.
• Continued surveillance for varicella disease among vaccinated persons is 
important to determine changes in the varicella epidemiology and whether 
changes in disease presentation with time since vaccination occur.
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a17 articles not available in English and only abstract reviewed. Abstracts did not indicate 
varicella complications or hospitalizations (15 articles) or reported cases were classified as 
herpes zoster (2 articles)
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Table 1
Overview of 34 References Describing Severe Breakthrough Varicella
















United Arab Emirates 1 (3%)
Uruguay 1 (3%)
Article Type
Post-licensure disease surveillance 13 (38%)
Case-report 13 (38%)
Post-licensure safety and/or immunogenicity report 6 (18%)
Pre-licensure safety and efficacy 1 (3%)
Outbreak investigation report 1 (3%)
Number of vaccine doses among patients described
1 Dose 22 (65%)




GSK VZV Vaccines 2 (6%)
Merck VZV Vaccines 20 (59%)
Oka, unspecified 3 (9%)
Okavax 1 (3%)
Multiple VZV Vaccine Types 7 (21%)
a
Two were published prior to vaccine licensure, one from Japan and other from the United States.
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b
Data are from Merck’s Varicella Zoster Virus Identification post-marketing safety surveillance program in European countries; report by country 
not available.
c
These 2 articles described reports of hospitalized breakthrough varicella in persons who had received one or two doses of varicella vaccine.
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Table 2
Breakthrough Varicella with Disseminated Varicella-Zoster Virus (VZV) Infection with Organ Involvement in 
Addition to Skin
Complication Category # Articles # Breakthrough 
Varicella Casesa
Diagnoses
Pneumonia 515, 23–26 8–9b,c Pneumonia
Neurologic 1110, 15, 18, 23, 24, 27–32 18–24b,f Meningitis, Encephalitis, Acute cerebellar ataxia, 
Transverse myelitis, Cerebellitis
Hematologic 915, 16, 18, 23, 26, 28, 34–36 10–11b,c,d,e Neutropenia, Thrombocytopenia, Pancytopenia, 
possible Macrophage activation syndrome, 
Hemorrhagia, Disseminated intravascular 
coagulation
Ocular 523, 24, 34, 37, 38 5d Keratitis, Conjunctivitis, Subconjunctival 
hemorrhage, Retinitis, Blurred vision, Hemorrhagic 
retinitis
Renal 211, 39 2 Gross hematuria, Nephrotic syndrome
Hepatic 418, 36, 40, 41 3e Hepatomegaly, Hepatitis, Hepatic necrosis
Secondary infections and Sepsis 716, 18, 23, 24, 35, 36, 42 8e,f Specific organism that caused sepsis was reported 
in 3 cases (Staph aureus in 1 case and Group A 
streptococcus in 2 cases)
Other 424, 27, 35, 43 4f Hypotension, Transient hearing loss, Myocarditis, 
Multi-organ failure
Deaths 816, 18, 23, 24, 30, 36, 41, 43 6e,g
Total unique case-patients with any 
of the complications above
25 52–60
a
A breakthrough case may have had multiple clinical features and is included in more than one organ system category.
b
It is likely that some of the cases were included in multiple articles. This is why we have included a range of total number of unique breakthrough 
cases in each of the respective complication categories, which is based on our determination of the information presented in the articles.
c
The case described by Pillegi et al26 developed pneumonia and hematologic complications and was included in both complication categories.
d
The case described by Kakish et al34 developed ocular and hematologic complications and was included in both complication categories.
e
The case described by Sharrar et al18 and Wise et al36 developed hepatic complications and sepsis, and ultimately died; this case was included 
under all 3 complication categories. The case described by Galea et al24 and Leung et al16 developed hematologic complications and sepsis, and 
ultimately died; she was included in all 3 complication categories.
f
The case described by Kwak et al35 who developed sepsis also developed hypotension. The case described by Schwab et al27 with neurologic 
complications also developed transient hearing loss.
g
All deaths were previously included in at least one of the other complication categories.
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